sj-docx-1-tah-10.1177_20406207211035272 – Supplemental material for Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study

Vitkon, Roy; Netanely, Dan; Levi, Shai; Ziv-Baran, Tomer; Ben-Yzak, Ronit; Katz, Ben-Zion; Benyamini, Noam; Trestman, Svetlana; Mittelman, Moshe; Cohen, Yael; Avivi, Irit

doi:10.25384/SAGE.15070649.v1

sj-docx-1-tah-10.1177_20406207211035272.docx (42.62 kB)

sj-docx-1-tah-10.1177_20406207211035272 – Supplemental material for Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study

journal contribution

posted on 2021-07-29, 00:06 authored by Roy Vitkon, Dan Netanely, Shai Levi, Tomer Ziv-Baran, Ronit Ben-Yzak, Ben-Zion Katz, Noam Benyamini, Svetlana Trestman, Moshe Mittelman, Yael Cohen, Irit Avivi

Supplemental material, sj-docx-1-tah-10.1177_20406207211035272 for Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study by Roy Vitkon, Dan Netanely, Shai Levi, Tomer Ziv-Baran, Ronit Ben-Yzak, Ben-Zion Katz, Noam Benyamini, Svetlana Trestman, Moshe Mittelman, Yael Cohen and Irit Avivi in Therapeutic Advances in Hematology